JP2019512495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512495A5 JP2019512495A5 JP2018548236A JP2018548236A JP2019512495A5 JP 2019512495 A5 JP2019512495 A5 JP 2019512495A5 JP 2018548236 A JP2018548236 A JP 2018548236A JP 2018548236 A JP2018548236 A JP 2018548236A JP 2019512495 A5 JP2019512495 A5 JP 2019512495A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- salt
- methylpiperazin
- pyran
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 9
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 8
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 8
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- -1 tetrahydro-2H-pyran-4-ylamino Chemical group 0.000 claims 2
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314700P | 2016-03-29 | 2016-03-29 | |
| US62/314700 | 2016-03-29 | ||
| US201662368343P | 2016-07-29 | 2016-07-29 | |
| US62/368343 | 2016-07-29 | ||
| PCT/JP2017/012293 WO2017170348A1 (en) | 2016-03-29 | 2017-03-27 | Combination therapy for the treatment of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512495A JP2019512495A (ja) | 2019-05-16 |
| JP2019512495A5 true JP2019512495A5 (cg-RX-API-DMAC10.html) | 2020-04-09 |
Family
ID=59965623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548236A Pending JP2019512495A (ja) | 2016-03-29 | 2017-03-27 | 急性骨髄性白血病の治療のための併用療法 |
Country Status (10)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| EA202191984A1 (ru) * | 2019-02-22 | 2021-11-19 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза |
| MY204603A (en) | 2019-04-03 | 2024-09-05 | Astellas Pharma Inc | Pharmaceutical composition |
| MX2021015724A (es) | 2019-06-27 | 2022-05-16 | Hanmi Pharm Ind Co Ltd | Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos. |
| JP2022552336A (ja) * | 2019-10-14 | 2022-12-15 | アストラゼネカ・アクチエボラーグ | 造血器悪性腫瘍を治療するための併用療法 |
| AU2020370110A1 (en) * | 2019-10-21 | 2022-05-26 | Rhizen Pharmaceuticals Ag | Compositions comprising a DHODH inhibitor for the treatment of acute myeloid leukemia |
| EP4370506A1 (en) | 2021-12-30 | 2024-05-22 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| KR102559124B1 (ko) | 2022-08-25 | 2023-07-26 | 주식회사 엔젠바이오 | Flt3 유전자 증폭용 조성물 및 이의 용도 |
-
2017
- 2017-03-27 BR BR112018069111-9A patent/BR112018069111A2/pt not_active Application Discontinuation
- 2017-03-27 EP EP17774885.2A patent/EP3436014A4/en not_active Withdrawn
- 2017-03-27 WO PCT/JP2017/012293 patent/WO2017170348A1/en not_active Ceased
- 2017-03-27 CA CA3018155A patent/CA3018155A1/en not_active Abandoned
- 2017-03-27 JP JP2018548236A patent/JP2019512495A/ja active Pending
- 2017-03-27 US US16/089,603 patent/US20190117649A1/en not_active Abandoned
- 2017-03-27 KR KR1020187028124A patent/KR20180124055A/ko not_active Withdrawn
- 2017-03-27 RU RU2018134167A patent/RU2018134167A/ru not_active Application Discontinuation
- 2017-03-27 MX MX2018011975A patent/MX2018011975A/es unknown
- 2017-03-27 CN CN201780021735.4A patent/CN108883109A/zh active Pending
-
2020
- 2020-07-30 US US16/943,379 patent/US20200360372A1/en not_active Abandoned